Evidence map›Paper›PMID 19522023›Full record

Trial reportWorld journal of gastroenterology2009

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.

Li-Jing Zhang, Shi-Yan Wang, Xiao-Hui Huo, Zhen-Long Zhu, Jian-Kun Chu, Jin-Cheng Ma, Dong-Sheng Cui, Ping Gu, Zeng-Ren Zhao, Ming-Wei Wang and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Review
  5. Article
  6. Article
  7. Review
  8. Lamb's tripe extract and vitamin BWorld journal of clinical cases · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Gastric cancer: prevention, screening and early diagnosis.World journal of gastroenterology · 2014
    Review
  15. Article
  16. Review
  17. Follow-up of intestinal metaplasia in the stomach: When, how and why.World journal of gastrointestinal oncology · 2012
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Li-Jing ZhangDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, Hong Kong, China.
Shi-Yan Wang
Xiao-Hui Huo
Zhen-Long Zhu
Jian-Kun Chu
Jin-Cheng Ma
Dong-Sheng Cui
Ping Gu
Zeng-Ren Zhao
Ming-Wei Wang
Jun Yu
Shariati Hospital · IRUniversity of Padua · ITChinese University of Hong Kong · CNFirst Affiliated Hospital of Hebei Medical University · CNHebei Medical University · CNNational Natural Science Foundation of China · CNPrince of Wales Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate whether celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, could reduce the severity of gastric precancerous lesions following Helicobacter pylori (H pylori) eradication.

methodsH pylori-eradicated patients with gastric precancerous lesions randomly received either celecoxib (n = 30) or placebo (n = 30) for up to 3 mo. COX-2 expression and activity was determined by immunostaining and prostaglandin E(2) (PGE(2)) assay, cell proliferation by Ki-67 immunostaining, apoptosis by TUNEL staining and angiogenesis by microvascular density (MVD) assay using CD31 staining.

resultsCOX-2 protein expression was significantly increased in gastric precancerous lesions (atrophy, intestinal metaplasia and dysplasia, respectively) compared with chronic gastritis, and was concomitant with an increase in cell proliferation and angiogenesis. A significant improvement in precancerous lesions was observed in patients who received celecoxib compared with those who received placebo (P < 0.001). Of these three changes, 84.6% of sites with dysplasia regressed in patients treated with celecoxib (P = 0.002) compared with 60% in the placebo group, suggesting that celecoxib was effective on the regression of dysplasia. COX-2 protein expression (P < 0.001) and COX-2 activity (P < 0.001) in the gastric tissues were consistently lower in celecoxib-treated patients compared with the placebo-treated subjects. Moreover, it was also shown that celecoxib suppressed cell proliferation (P < 0.01), induced cell apoptosis (P < 0.01) and inhibited angiogenesis with decreased MVD (P < 0.001). However, all of these effects were not seen in placebo-treated subjects. Furthermore, COX-2 inhibition resulted in the up-regulation of PPARgamma expression, a protective molecule with anti-neoplastic effects.

conclusionH pylori eradication therapy followed by celecoxib treatment improves gastric precancerous lesions by inhibiting COX-2 activity, inducing apoptosis, and suppressing cell proliferation and angiogenesis.

Indexed as

Cyclooxygenase 2 InhibitorsPyrazolesSulfonamidesAdultAgedApoptosisCelecoxibCell ProliferationCyclooxygenase 2Disease ProgressionHelicobacter InfectionsHelicobacter pyloriHumansKi-67 AntigenMiddle AgedNeovascularization, PathologicCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsKi-67 AntigenPlacebosPPAR gammaPTGS2 protein, humanPyrazolesSulfonamides

Identifiers

PMID19522023
PMCPMC2695888
OpenAlexW2101105397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.